Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Humira Drug Market?

In recent times, the Humira drug market has experienced a robust expansion. The market size is anticipated to increase from $9.74 billion in 2024 to $10.43 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. Several contributing factors to this growth during the historical period include the introduction of biologics, advances in biotechnology, consumer demand for effective treatments, as well as doctor acceptance and their prescribing habits.

What Growth Rate Is Forecasted for the Humira Drug Market by 2029?

The market size of the humira drug is anticipated to witness substantial expansion in the coming years. It is predicted to reach $14.19 billion by 2029, with a compound annual growth rate (CAGR) of 8.0%. Factors such as the emergence of biosimilar markets, alterations in healthcare policies, emphasis on cost-efficiency, investment in research and development, as well as precision medicine and personalized therapies, are contributing to this growth during the forecast period. Major trends anticipated include the creation of real-world evidences, extended application in paediatric groups, a move towards self-administered medication, value-oriented pricing models, and the advancement of targeted therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11934&type=smp

Which Key Companies Are Shaping the Future of the Humira Drug Market?

Major companies operating in the humira drug market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Celltrion Healthcare Co. Ltd., Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mochida Pharmaceutical Co. Ltd., Innovent Biologics Inc., Biocad Biopharmaceutical Company, Shanghai Henlius Biotech Inc., Glenmark Pharmaceuticals Ltd., Samsung Bioepis Co Ltd., Hetero Healthcare Ltd., Coherus BioSciences Inc., CinnaGen Co., Alvotech Holdings S.A, Reliance Life Sciences Private Limited, Momenta Pharmaceuticals Inc., Bio-Thera Solutions Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., BioXpress Therapeutics SA, Alteogen Inc., Prestige BioPharma Pte. Ltd.

Which Factors Are Driving Demand in the Humira Drug Industry?

The projected increase in the prevalence of autoimmune diseases is anticipated to fuel the expansion of the humira drug market. An autoimmune disease is a condition where the immune system initiates an attack on healthy tissues and cells within the body. The humira drug serves to alleviate the pain and inflammation caused by a variety of autoimmune diseases, and hence, an uptick in the prevalence of such diseases amplifies the demand for the humira drug. For example, in March 2024, the National Health Council, a US-based non-profit organization, reported that approximately 50 million Americans are affected by autoimmune diseases. Nonetheless, due to complications in diagnosing these conditions, the actual number may be higher. It is alarming to note that autoimmunity is nearing epidemic levels, with a few researches indicating an annual surge of 3-12%. Hence, the escalating prevalence rate of autoimmune diseases will instigate the growth of the HUMIRA drug market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11934&type=smp

How Is the Humira Drug Market Segmented by Several Divisions?

The humira drug market covered in this report is segmented –

1) By Type: Humira Syringe, Humira Pen

2) By Application: Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other Applications

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Humira Syringe: Pre-Filled Syringe, Disposable Syringe

2) By Humira Pen: Auto-Injector Pen, Pre-Filled Injection Pen

What are the Emerging Market Trends Driving the Growth of the Humira Drug Industry?

A prevailing trend in the humira drug market is product innovation. In order to maintain their market standing, prominent companies in this sector are creating novel biologics and biosimilars. As an example, Swiss pharmaceutical company, Sandoz, launched Biosimilar Hyrimoz (adalimumab) in April 2023, a citrate-free high-concentration formulation (HCF) that was approved by the European Commission. The introduction of this 100 mg/mL adalimumab citrate-free HCF translates to a 50% decrease in injection volume, reducing the number of injections required for patients who select 80 mg/mL or higher dosing. This is applicable to a range of conditions, such as rheumatic diseases and Crohn’s disease, enhancing the patient experience.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/humira-drug-global-market-report

Which Regions Are Driving Growth in the Humira Drug Market?

North America was the largest region in the humira drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humira drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11934

This Report Delivers Insight On:

1. How big is the humira drug market, and how is it changing globally?

2. Who are the major companies in the humira drug market, and how are they performing?

3. What are the key opportunities and risks in the humira drug market right now?

4. Which products or customer segments are growing the most in the humira drug market?

5. What factors are helping or slowing down the growth of the humira drug market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model